Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
- PMID: 10597776
- DOI: 10.1097/00002030-199912030-00006
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
Abstract
Objective: It is thought as a consequence of continuous replication, HIV-1 has acquired an optimal fitness state and that suboptimal antiretroviral therapy selects for drug resistant variants which show impaired fitness in the absence of the drug. In this paper we studied the evolution and fitness of viral populations appearing in a patient who received protease monotherapy.
Methods: Two factors contributing to fitness, drug resistance and protease catalytic activity, were studied at the enzymatic and virological level.
Results: The first drug resistant viral variants that were selected in vivo harboured one to three protease substitutions. These mutants showed reduced protease activity and consequently a reduction in viral replication capacity. During continued in vivo replication of these viruses in the presence of the drug, novel variants harbouring additional substitutions in the viral protease appeared. These variants did not display any further increase in drug resistance but demonstrated clearly increased protease activity. Consequently the replication capacity of these viruses was raised to a level at which they replicated better than the original wild-type virus.
Conclusion: This study indicates that the viral population in the patient does not have to represent the fittest possible variants, and thus antiretroviral therapy may drive the viral population first through a lower fitness level and then to a higher fitness level.
Similar articles
-
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):487-97. doi: 10.1089/08892220151126526. AIDS Res Hum Retroviruses. 2001. PMID: 11350662
-
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.J Virol. 1997 Sep;71(9):6662-70. doi: 10.1128/JVI.71.9.6662-6670.1997. J Virol. 1997. PMID: 9261388 Free PMC article.
-
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.J Virol. 1998 Sep;72(9):7632-7. doi: 10.1128/JVI.72.9.7632-7637.1998. J Virol. 1998. PMID: 9696866 Free PMC article.
-
HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness.J Biomed Sci. 1999 Sep-Oct;6(5):298-305. doi: 10.1007/BF02253518. J Biomed Sci. 1999. PMID: 10494036 Review.
-
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.AIDS Rev. 2008 Jul-Sep;10(3):131-42. AIDS Rev. 2008. PMID: 18820715 Free PMC article. Review.
Cited by
-
Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.J Virol. 2006 Mar;80(5):2380-9. doi: 10.1128/JVI.80.5.2380-2389.2006. J Virol. 2006. PMID: 16474144 Free PMC article.
-
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression.J Virol. 2005 Jul;79(14):9006-18. doi: 10.1128/JVI.79.14.9006-9018.2005. J Virol. 2005. PMID: 15994794 Free PMC article.
-
Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.BMC Bioinformatics. 2009 Aug 27;10 Suppl 8(Suppl 8):S10. doi: 10.1186/1471-2105-10-S8-S10. BMC Bioinformatics. 2009. PMID: 19758465 Free PMC article.
-
Drug-class specific impact of antivirals on the reproductive capacity of HIV.PLoS Comput Biol. 2010 Mar 26;6(3):e1000720. doi: 10.1371/journal.pcbi.1000720. PLoS Comput Biol. 2010. PMID: 20361047 Free PMC article.
-
Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I.Biochem Biophys Res Commun. 2019 Jun 30;514(3):974-978. doi: 10.1016/j.bbrc.2019.05.064. Epub 2019 May 12. Biochem Biophys Res Commun. 2019. PMID: 31092330 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical